{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:22:27Z","timestamp":1771543347050,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.7759\/cureus.75791","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:00:26Z","timestamp":1734350426000},"source":"Crossref","is-referenced-by-count":1,"title":["Methylenetetrahydrofolate Reductase (MTHFR) Variants and Severe Capecitabine Toxicity: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Li","family":"Lingyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Linjun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Wenjun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?","volume":"50","author":"Meulendijks D","year":"2016","unstructured":"Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?. Cancer Treat Rev. 2016, 50:23-34. 10.1016\/j.ctrv.2016.08.002","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.12.010","article-title":"Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing","volume":"1863","author":"van Kuilenburg AB","year":"2017","unstructured":"van Kuilenburg AB, Meijer J, Maurer D, et al.. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. Biochim Biophys Acta Mol Basis Dis. 2017, 1863:721-730. 10.1016\/j.bbadis.2016.12.010","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.1.4","article-title":"Dihydropyrimidine dehydrogenase deficiency: to screen or not to screen?","volume":"11","author":"Vogel WH","year":"2020","unstructured":"Vogel WH, Minhas A, Baumrucker S. Dihydropyrimidine dehydrogenase deficiency: to screen or not to screen?. J Adv Pract Oncol. 2020, 11:68-73. 10.6004\/jadpro.2020.11.1.4","journal-title":"J Adv Pract Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49215","article-title":"Thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms associated with severe capecitabine toxicity: the first case from Saudi Arabia","volume":"15","author":"Bukhari N","year":"2023","unstructured":"Bukhari N, Al-Mohanna H, Almsned F. Thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms associated with severe capecitabine toxicity: the first case from Saudi Arabia. Cureus. 2023, 15:e49215. 10.7759\/cureus.49215","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04236-y","article-title":"Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population","volume":"87","author":"Saarenheimo J","year":"2021","unstructured":"Saarenheimo J, Wahid N, Eigeliene N, et al.. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. Cancer Chemother Pharmacol. 2021, 87:657-663. 10.1007\/s00280-021-04236-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000753","article-title":"Capecitabine toxicity and dihydropyrimidine dehydrogenase deficiency","volume":"25","author":"Tariq Z","year":"2018","unstructured":"Tariq Z, Mudge R, Phillips S. Capecitabine toxicity and dihydropyrimidine dehydrogenase deficiency. Am J Ther. 2018, 25:e742-e743. 10.1097\/MJT.0000000000000753","journal-title":"Am J Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1684\/abc.2010.0394","article-title":"Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine [Article in French]","volume":"68","author":"Boisdron-Celle M","year":"2010","unstructured":"Boisdron-Celle M, Morel A, Gamelin E. Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine [Article in French]. Ann Biol Clin (Paris). 2010, 68:27-32. 10.1684\/abc.2010.0394","journal-title":"Ann Biol Clin (Paris)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000510258","article-title":"Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper","volume":"43","author":"W\u00f6rmann B","year":"2020","unstructured":"W\u00f6rmann B, Bokemeyer C, Burmeister T, et al.. Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat. 2020, 43:628-636. 10.1159\/000510258","journal-title":"Oncol Res Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks LM","year":"2017","unstructured":"Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JH. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol. 2017, 28:2915-2922. 10.1093\/annonc\/mdx411","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz U","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018, 103:210-216. 10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14428","article-title":"Association of C677T and A1298C MTHFR polymorphisms and fluoropyrimidine-induced toxicity in mestizo patients with metastatic colorectal cancer","volume":"40","author":"Ramos-Esquivel A","year":"2020","unstructured":"Ramos-Esquivel A, Chinchilla R, Valle M. Association of C677T and A1298C MTHFR polymorphisms and fluoropyrimidine-induced toxicity in mestizo patients with metastatic colorectal cancer. Anticancer Res. 2020, 40:4263-4270. 10.21873\/anticanres.14428","journal-title":"Anticancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.12.004","article-title":"C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation","volume":"45","author":"De Mattia E","year":"2009","unstructured":"De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009, 45:1333-1351. 10.1016\/j.ejca.2008.12.004","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040045","article-title":"DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients","volume":"8","author":"Amirfallah A","year":"2018","unstructured":"Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I, Basbinar Y. DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med. 2018, 8:45. 10.3390\/jpm8040045","journal-title":"J Pers Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000429","article-title":"The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer","volume":"27","author":"Romiti A","year":"2016","unstructured":"Romiti A, Roberto M, D'Antonio C, et al.. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anticancer Drugs. 2016, 27:1044-1049. 10.1097\/CAD.0000000000000429","journal-title":"Anticancer Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp046","article-title":"MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer","volume":"20","author":"Afzal S","year":"2009","unstructured":"Afzal S, Jensen SA, Vainer B, et al.. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009, 20:1660-1666. 10.1093\/annonc\/mdp046","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.11.1561","article-title":"Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer","volume":"8","author":"Etienne-Grimaldi MC","year":"2007","unstructured":"Etienne-Grimaldi MC, Francoual M, Formento JL, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007, 8:1561-1566. 10.2217\/14622416.8.11.1561","journal-title":"Pharmacogenomics"},{"key":"ref17","article-title":"Association of the 677c -->T polymorphism in the MTHFR gene with colorectal cancer in mexican patients","volume":"6","author":"Gallegos-Arreola MP","year":"2009","unstructured":"Gallegos-Arreola MP, Garcia-Ortiz JE, Figuera LE, Puebla-P\u00e9rez AM, Morgan-Villela G, Z\u00fa\u00f1iga-Gonz\u00e1lez GM. Association of the 677c -->T polymorphism in the MTHFR gene with colorectal cancer in mexican patients. Cancer Genomics Proteomics. 2009, 6:183-188.","journal-title":"Cancer Genomics Proteomics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0320","article-title":"Pharmacogenetics of capecitabine in advanced breast cancer patients","volume":"12","author":"Largillier R","year":"2006","unstructured":"Largillier R, Etienne-Grimaldi MC, Formento JL, et al.. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res. 2006, 12:5496-5502. 10.1158\/1078-0432.CCR-06-0320","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.262","article-title":"Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity","volume":"108","author":"Loganayagam A","year":"2013","unstructured":"Loganayagam A, Arenas Hernandez M, Corrigan A, et al.. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013, 108:2505-2515. 10.1038\/bjc.2013.262","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis","volume":"32","author":"Rosmarin D","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, et al.. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014, 32:1031-1039. 10.1200\/JCO.2013.51.1857","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0304","article-title":"Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients","volume":"17","author":"Afzal S","year":"2011","unstructured":"Afzal S, Gusella M, Vainer B, et al.. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011, 17:3822-3829. 10.1158\/1078-0432.CCR-11-0304","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.798","article-title":"Pancytopenia and severe gastrointestinal toxicities associated with 5-fluorouracil in a patient with thymidylate synthase (TYMS) polymorphism","volume":"8","author":"Wang B","year":"2016","unstructured":"Wang B, Walsh SJ, Saif MW. Pancytopenia and severe gastrointestinal toxicities associated with 5-fluorouracil in a patient with thymidylate synthase (TYMS) polymorphism. Cureus. 2016, 8:e798. 10.7759\/cureus.798","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328351875d","article-title":"Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis","volume":"22","author":"Jennings BA","year":"2012","unstructured":"Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics. 2012, 22:290-304. 10.1097\/FPC.0b013e328351875d","journal-title":"Pharmacogenet Genomics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.08.001","article-title":"The role of pharmacogenetics in capecitabine efficacy and toxicity","volume":"50","author":"Lam SW","year":"2016","unstructured":"Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016, 50:9-22. 10.1016\/j.ctrv.2016.08.001","journal-title":"Cancer Treat Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112548","article-title":"Association of single-nucleotide polymorphisms in capecitabine bioactivation pathway with adjuvant therapy safety in colorectal cancer patients","volume":"15","author":"Cura Y","year":"2023","unstructured":"Cura Y, S\u00e1nchez-Mart\u00edn A, M\u00e1rquez-Pete N, Gonz\u00e1lez-Flores E, Mart\u00ednez-Mart\u00ednez F, P\u00e9rez-Ram\u00edrez C, Jim\u00e9nez-Morales A. Association of single-nucleotide polymorphisms in capecitabine bioactivation pathway with adjuvant therapy safety in colorectal cancer patients. Pharmaceutics. 2023, 15:2548. 10.3390\/pharmaceutics15112548","journal-title":"Pharmaceutics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.03.021","article-title":"Identification of new SNPs associated with severe toxicity to capecitabine","volume":"120","author":"Pellicer M","year":"2017","unstructured":"Pellicer M, Garc\u00eda-Gonz\u00e1lez X, Garc\u00eda MI, et al.. Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol Res. 2017, 120:133-137. 10.1016\/j.phrs.2017.03.021","journal-title":"Pharmacol Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1741","article-title":"A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome","volume":"17","author":"Caronia D","year":"2011","unstructured":"Caronia D, Martin M, Sastre J, et al.. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011, 17:2006-2013. 10.1158\/1078-0432.CCR-10-1741","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.641","article-title":"Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity","volume":"102","author":"Hamzic S","year":"2017","unstructured":"Hamzic S, Kummer D, Milesi S, et al.. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity. Clin Pharmacol Ther. 2017, 102:796-804. 10.1002\/cpt.641","journal-title":"Clin Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078053","article-title":"Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines","volume":"8","author":"Jennings BA","year":"2013","unstructured":"Jennings BA, Loke YK, Skinner J, et al.. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One. 2013, 8:e78053. 10.1371\/journal.pone.0078053","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.81","article-title":"Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies","volume":"17","author":"Meulendijks D","year":"2017","unstructured":"Meulendijks D, Rozeman EA, Cats A, et al.. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J. 2017, 17:441-451. 10.1038\/tpj.2016.81","journal-title":"Pharmacogenomics J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2018.42.009","article-title":"Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis [Article in Chinese]","volume":"98","author":"Chen WC","year":"2018","unstructured":"Chen WC, Wu G, Zhang W, et al.. Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis [Article in Chinese]. Zhonghua Yi Xue Za Zhi. 2018, 98:3420-3425. 10.3760\/cma.j.issn.0376-2491.2018.42.009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122036","article-title":"Clinical relevance of novel polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene in patients with severe fluoropyrimidine toxicity: a Spanish case-control study","volume":"13","author":"Soria-Chacartegui P","year":"2021","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, L\u00f3pez-Fern\u00e1ndez LA, Navares-G\u00f3mez M, Mej\u00eda-Abril G, Abad-Santos F, Zubiaur P. Clinical relevance of novel polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene in patients with severe fluoropyrimidine toxicity: a Spanish case-control study. Pharmaceutics. 2021, 13:2036. 10.3390\/pharmaceutics13122036","journal-title":"Pharmaceutics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322960-methylenetetrahydrofolate-reductase-mthfr-variants-and-severe-capecitabine-toxicity-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:00:29Z","timestamp":1734350429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322960-methylenetetrahydrofolate-reductase-mthfr-variants-and-severe-capecitabine-toxicity-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.75791","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}